Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

Posters

A Quantitative Systems Pharmacology (QSP) Model for Classical Homocystinuria Predicting Efficacy of Treatment

Posters HCU

Development of a Patient Identification Algorithm to Estimate Prevalence of Classical Homocystinuria (HCU) in the United States (US)

Posters HCU

Insights From the First Genetic Evaluation of a Longitudinal Natural History Study in Classical Homocystinuria (HCU)

Posters HCU

Population-based Incidence Estimates of Classical Homocystinuria Using the Genome Aggregation Database (gnomAD)

Posters

Skeletal Fragility In A Natural History Study Of Homocystinuria Due To Cystathionine Beta-synthase Deficiency Patients

Posters

Comorbid Diagnoses, Medications, and Healthcare Provider Types among Patients Diagnosed with Classical Homocystinuria

Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Posters

Alport Syndrome Natural History from the Rare Disease Registry: Associations with gene, variant type, and sex

Posters IgAN

Estimating delay in time to kidney failure ordeath for treatment effects on proteinuria inIgA nephropathy

Posters IgAN

Matching-adjusted indirect comparison of sparsentan vs. delayed-release formulationbudesonide for proteinuria reduction in adults with IgA nephropathy

Posters FSGS

Understanding the Impact of Immunoglobulin ANephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study(HONUS): Updated Results for IgAN in the United States (US)

Posters CTX

Prevalence of Cerebrotendinous Xanthomatosis (CTX) Among Patients Diagnosed With Juvenile-Onset Idiopathic Bilateral Cataracts

Posters

Genetic Testing Identified Causative Variants in Nearly 20% of Early-Onset Bilateral Cataracts Cases